Paracelsus-Elena-Klinik, Kassel, Klinikstrasse 16, 34128 Kassel, Germany.
Biomark Med. 2010 Oct;4(5):683-99. doi: 10.2217/bmm.10.90.
The pursuit of laboratory tests that allow for the reliable and inexpensive identification of subjects with parkinsonism represents a hot topic in translational neuroscience. This unmet need affects the counseling of presymptomatic, at-risk subjects and delays the accurate diagnosis of already symptomatic individuals. The absence of validated markers that are closely linked to the pathological disease process also compromises the objective monitoring of therapeutic interventions in clinical trials. Typical Parkinson's disease represents a heterogenous syndrome (but the majority of patients suffer from neurodegeneration) that is linked to the misprocessing of α-synuclein (α-Syn). The identification of α-Syn as a bona fide constituent of human cerebrospinal fluid and its quantification in early cross-sectional studies represent the beginning of a new chapter in Parkinson's disease research. It will determine what role, if any, cerebrospinal fluid α-Syn plays as a biomarker candidate in Lewy inclusion-positive forms of parkinsonism. This article focuses on the progress that has been made in seven recently published papers and highlights the challenges that lie ahead. We also provide specific information regarding standardized operating procedures for cerebrospinal fluid collection in PD biomarker research efforts.
对能够可靠且廉价地鉴定帕金森病患者的实验室检测方法的追求，是转化神经科学领域的一个热门话题。这种未满足的需求影响了对有患病风险的前驱期个体的咨询，并延误了已出现症状个体的准确诊断。缺乏与病理疾病过程密切相关的经过验证的标志物，也会影响临床试验中治疗干预的客观监测。典型的帕金森病是一种异质性综合征（但大多数患者都遭受神经退行性病变），与α-突触核蛋白（α-Syn）的错误处理有关。α-Syn 被确认为人类脑脊液中的一种真实成分，并且在早期的横断面研究中对其进行定量分析，这标志着帕金森病研究的一个新篇章的开始。它将确定脑脊液 α-Syn 是否以及在何种程度上作为路易体阳性帕金森病的生物标志物候选物发挥作用。本文重点介绍了最近发表的七篇论文所取得的进展，并强调了未来的挑战。我们还提供了关于帕金森病生物标志物研究中脑脊液采集的标准化操作程序的具体信息。
